Abstracts insurance, physician type, region, pre-dialysis co-morbidities, and pre-dialysis costs were used to evaluate the impact of pre-dialysis paricalcitol treatment on hospitalizations, outpatient services, and medication use in first year of dialysis. RESULTS: Multivariable analysis demonstrated predialysis paricalcitol use was associated with statistically significant reductions in all-cause hospitalizations (0.806, 95%CI: 0.684-0.950), all-cause outpatient services (0.953, 95%CI: 0.933-0.973) and CKDrelated hospitalizations (0.780, 95% CI: 0.635 -0.958); CKD-related outpatient visits (0.962, 95% CI: 0.938-0.987); and CKD-related medications (0.922, 95% CI: 0.852-0.996) in the first year of dialysis compared with no predialysis VDR activator treatment. CONCLUSIONS: Paricalcitol treatment for SHPT prior to dialysis is associated with fewer CKD-related medications; and all-cause and CKD-related outpatient services and hospitalizations in the first year of dialysis compared to no VDR activator treatment. Payers should consider these findings when make coverage decisions regarding the use of paricalcitol. Further studies are needed to confirm these results.
PUK12 ECONOMIC EVALUATION ON THE USE OF OXYBUTYNIN, TOLTERODINE, AND SOLIFENACIN IN PATIENTS WITH HYPERACTIVE BLADDER
De Lago Acosta A 1 , Salinas G 2 , Idrovo J 3 , Zapata L 4 , Alanís A 1 , Rico I 5 1 Laboratorios Liomont, Mexico, DF, Mexico, 2 Hospital Infantil de México Federico Gómez, México, DF, Mexico, 3 National Institute of Public Health, Cuernavaca, Morelos, Mexico, 4 Guia Mark, Mexico, DF, Mexico, 5 Guia Mark SA DE CV, Mexico, DF, Mexico OBJECTIVES: Hyperactive Bladder (HB) is a common, debilitating condition with a considerable negative impact on quality of life. The cost-effectiveness (CE) of three medications was evaluated for the treatment of patients with Hyperactive Bladder from the Mexican Institute of Social Security (IMSS) perspective. METHODS: CE analysis from the perspective of the service provider (IMSS). Since it is a chronic disease with different stages, a Markov model with monthly cycles in a 12-month temporal horizon was developed. Only direct medical costs were used in the analysis. Direct medical costs were estimated on a sample of patient files in two IMSS medical units. Criteria for inclusion was patients with more than 6 months of treatment. The effectiveness measurement was taken from literature and was defined as the percentage of patients that did not present symptoms of incontinence. Univariated and probabilistic sensitivity analyses were performed. RESULTS: The oxybutynin treatment reflected the lowest expected cost per patient treated for hyperactive bladder, US$545 (1 USD = 13.5MXN); followed by the solifenacin and tolterodine treatments, with a cost of US$680 and US$1,135, respectively. As for the effectiveness measurement, the percentage of patients that did not present incontinence within the temporal horizon of analysis was: with tolterodine 2.76%, with oxybutynin 7.11% and with solifenacin 7.46%. Therefore, cost effectiveness ratios interpreted as the cost per percentage point of patients that did not present HB are: oxybuynin US$77, solifenacin US$91 and tolterodine US$411. The incremental cost effectiveness analysis indicates that tolterodine is a dominated alternative and that oxybutynin and solifenacin are positioned within the efficiency line. Nonetheless, when conducting the probabilistic analysis, it was found that with US$411 available, a solifenacin treatment would be more cost effective for the institution. CONCLUSIONS: From an institutional perspective, solifenacine is a cost-effective alternative for treating patients with HB in the Mexican context.
PUK13 THE COST-EFFECTIVENESS OF EARLY SURGERY, ADDING BIOPSY, AND WATCHFUL WAITING IN THE MANAGEMENT OF SMALL SOLID RENAL MASSES: EVIDENCE FROM A MARKOV MODEL
Yu J 1 , Heilbrun M 1 , Smith K 2 , Zagoria R 3 1 University of Utah, Salt lake city, UT, USA, 2 University of Pittsburgh, Pittsburgh, PA, USA, 3 Wake Forest University, Winston-Salem, NC, USA OBJECTIVES: To compare the relative cost-effectiveness of three clinical strategies for managing T1a tumor (4 cm or smaller and limited to the kidney): early surgery upon detection of the tumor, adding percutaneous biopsy prior to surgery, and watchful waiting (WW) (monitor with computerized tomography every 6 months until the growth is greater than 2mm per year). METHODS: A Markov decision tree was used to estimate the expected survival in quality-adjusted life years (QALYs) and incremental cost-effectiveness (ICER) for each strategy from a societal perspective, based on literature-derived estimates for the probabilities and costs of different outcomes. Multiple one-way and probabilistic sensitivity analysis were conducted to examine the robustness of the results. RESULTS: In the base-case, adding biopsy before surgery improved survival by 0.018 QALYs compared with immediate surgery, at an incremental cost of $55,244/QALY, while the ICER of WW relative to surgery was $11,712/QALY. In the base-case, percutaneous biopsy is more expensive and less effective than WW. The treatment decision was most sensitive to variation of the degree of tumor growth that triggers surgery, utility of living with a mass during WW, and the probability of diagnostic biopsy for benign tumors. Choice of WW versus surgery critically depends on patients' preferences for tumor removal and the risk of recurrence post surgery. In probabilistic sensitivity analysis, surgery was the most favored strategy when the willingness to pay (WTP) is less than $10,000/QALY. WW is favored as WTP increases beyond $10,000/QALY, and biopsy was favored over surgery when WTP is > $60,000. CONCLUSIONS: Although WW results in the highest life-time utility, the favorability of WW depends on patients' preferences for living with a possibly malignant mass and natural history of watched masses during surveillance, which are poorly understood. Biopsy would be favored if its costs decrease and diagnostic certainty increases in the future.
PUK14 CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES FOR DIALYSIS PATIENTS: A CASE STUDY OF SEVELAMER FOR THE TREATMENT OF HYPERPHOSPHATEMIA
Cornerstone Research Group Inc., Burlington, ON, Canada, 2 Humber River Regional Hospital, Weston, ON, Canada, 3 Genzyme Corporation, Cambridge, MA, USA OBJECTIVES: Therapies that extend the lives of dialysis patients can not demonstrate cost-effectiveness if dialysis costs are included. This study examined the cost-effectiveness of sevelamer versus calcium-based binders (CBBs) as treatment for hyperphosphatemia in dialysis patients and, within this context, the suitability of the inclusion of dialysis costs. METHODS: A Markov model estimated life years, incremental cost per life year gained (LYG) and incremental quality-adjusted life year gained (QALYG). Treatment-specific survival was derived from the Dialysis Clinical Outcomes Revisited (DCOR) study and extrapolated using a Weibull regression model. The base case analysis used resource use and survival data for DCOR patients ≥65 years combined with Canadian unit costs and utility weights from published literature. Dialysis costs were excluded from the base case analysis, as dialysis use is unrelated to phosphate binder choice. Analyses were conducted for a 10-year time horizon using the Alberta Health Care System perspective, with costs and outcomes discounted at 5% per year. RESULTS: Compared with CBBs, sevelamer resulted in a gain of 1.02 LYs and 0.62 QALYs/ patient (discounted) producing ratios of $20,847/LYG and $34,175/ QALYG. Over a lifetime horizon, the cost/LYG and cost/QALYG were $23,804 and $39,022, respectively. Inclusion of dialysis costs resulted in ratios above $90,000/LYG and $150,000/QALYG. CONCLUSIONS: The study highlights the challenges associated with assessing funding of therapies that extend life in dialysis patients and discusses the applicability of dialysis costs in such situations. It found that sevelamer offers good value for money compared to CBBs in the treatment of hyperphosphatemia in patients ≥65 years old receiving dialysis.
PUK15 COST-EFFECTIVENESS ANALYSIS OF THREE MONTHS TREATMENT WITH FESOTERODINE COMPARED TO GENERIC OXYBUTYNIN EXTENDED-RELEASE IN WOMEN WITH URINARY INCONTINENCE FROM A THIRD PARTY PAYER PERSPECTIVE
Blaser DA 1 , Kohn MJ 2 , Ousterhout M 1 1 UMass Medical School, Shrewsbury , MA, USA, 2 Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA OBJECTIVES: Six pharmacological agents are FDA-approved to treat urinary incontinence, a condition that has economic costs of $19 billion US dollars per year. This study compares the recently FDA-approved fesoterodine to generic oxybutynin extended-release (ER) to identify which agent is more cost-effective in the treatment of urinary incontinence for three months in women over age 60 from the third party payer perspective. METHODS: A search was conducted using the MEDLINE Database from 1980-2009 for the terms "oxybutynin," "fesoterodine," "randomized controlled trial," and "urinary incontinence." Five articles evaluating clinical improvement among a predominantly female population were identified for inclusion. For the purpose of this analysis, an effectively treated patient was defined as a patient demonstrating a decrease of 14 or more episodes per week of each of the following: urge
